|252.39||-0.1200||-0.05%||Vol 995.36K||1Y Perf 6.72%|
|Dec 6th, 2023 16:00 DELAYED|
|- -||- -%|
|Target Price||249.68||Analyst Rating||Strong Buy 1.38|
|Potential %||-1.07||Finscreener Ranking||+ 38.14|
|Insiders Trans % 3/6/12 mo.||76/70/-17||Value Ranking||☆ 33.33|
|Insiders Value % 3/6/12 mo.||97/82/-2||Growth Ranking||★ 39.73|
|Insiders Shares Cnt. % 3/6/12 mo.||97/85/7||Income Ranking||+ 27.16|
|Price Range Ratio 52W %||40.98||Earnings Rating||Sell|
|Market Cap||67.55B||Earnings Date||26th Jan 2024|
Today's Price Range
5 Year PE Ratio Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||26th Jan 2024|
|Estimated EPS Next Report||5.02|
|EPS Growth Next 5 Years %||9.60|
|Avg. Weekly Volume||1.34M|
|Avg. Monthly Volume||1.45M|
|Avg. Quarterly Volume||1.36M|
HCA Healthcare Inc. (NYSE: HCA) stock closed at 252.39 per share at the end of the most recent trading day (a -0.05% change compared to the prior day closing price) with a volume of 995.36K shares and market capitalization of 67.55B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Healthcare Providers & Services industry, Healthcare sector and employs 275000 people. HCA Healthcare Inc. CEO is Samuel N. Hazen.
The one-year performance of HCA Healthcare Inc. stock is 6.72%, while year-to-date (YTD) performance is 5.18%. HCA stock has a five-year performance of 85.77%. Its 52-week range is between 215.96 and 304.86, which gives HCA stock a 52-week price range ratio of 40.98%
HCA Healthcare Inc. currently has a PE ratio of 14.40, a price-to-book (PB) ratio of 292.01, a price-to-sale (PS) ratio of 1.58, a price to cashflow ratio of 9.10, a PEG ratio of 1.50, a ROA of 11.50%, a ROC of 5.19% and a ROE of -271.60%. The company’s profit margin is 9.36%, its EBITDA margin is 20.90%, and its revenue ttm is $44.74 Billion , which makes it $158.24 revenue per share.
Of the last four earnings reports from HCA Healthcare Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $5.02 for the next earnings report. HCA Healthcare Inc.’s next earnings report date is 26th Jan 2024.
The consensus rating of Wall Street analysts for HCA Healthcare Inc. is Strong Buy (1.38), with a target price of $249.68, which is -1.07% compared to the current price. The earnings rating for HCA Healthcare Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
HCA Healthcare Inc. has a dividend yield of 0.90% with a dividend per share of $2.24 and a payout ratio of 6.00%.
HCA Healthcare Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 15.29, ATR14 : 5.41, CCI20 : 81.72, Chaikin Money Flow : -0.01, MACD : 4.20, Money Flow Index : 74.07, ROC : 5.03, RSI : 59.40, STOCH (14,3) : 75.15, STOCH RSI : 0.30, UO : 54.83, Williams %R : -24.85), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of HCA Healthcare Inc. in the last 12-months were: Akdamar Erol R. (Option Excercise at a value of $1 286 795), Berres Jennifer (Sold 4 000 shares of value $1 020 920 ), Bill B. Rutherford (Option Excercise at a value of $4 430 180), Bill B. Rutherford (Sold 30 000 shares of value $7 745 700 ), Billington Phillip (Option Excercise at a value of $576 839), Christopher F. Wyatt (Option Excercise at a value of $983 520), Christopher F. Wyatt (Sold 4 900 shares of value $1 241 170 ), Cuffe Michael (Option Excercise at a value of $3 239 143), Cuffe Michael (Sold 16 556 shares of value $4 599 868 ), Deborah M. Reiner (Sold 7 941 shares of value $2 045 699 ), Erol R Akdamar (Option Excercise at a value of $407 700), Erol R Akdamar (Sold 3 000 shares of value $775 891 ), Foster Jon (Option Excercise at a value of $2 486 869), Foster Jon (Sold 16 424 shares of value $4 138 519 ), Hazen Samuel (Option Excercise at a value of $4 068 640), Jennifer L. Berres (Sold 4 000 shares of value $1 020 912 ), Jon M. Foster (Option Excercise at a value of $2 486 869), Jon M. Foster (Sold 16 424 shares of value $4 138 480 ), Kathleen M. Whalen (Option Excercise at a value of $86 975), Kathleen M. Whalen (Sold 1 734 shares of value $457 097 ), Kathryn A. Torres (Option Excercise at a value of $462 807), Michael R. Mcalevey (Sold 0 shares of value $0 ), Michael S. Cuffe (Sold 4 000 shares of value $1 028 440 ), P. Martin Paslick (Option Excercise at a value of $2 486 666), P. Martin Paslick (Sold 15 833 shares of value $4 231 904 ), Richard A Hammett (Option Excercise at a value of $0), Sammie S. Mosier (Option Excercise at a value of $0), Samuel N. Hazen (Option Excercise at a value of $4 068 640), Timothy M McManus (Sold 7 900 shares of value $2 007 067 ), Torres Kathryn (Option Excercise at a value of $1 714 339), Torres Kathryn (Sold 9 677 shares of value $2 690 423 ), Whalen Kathleen (Sold 0 shares of value $-86 975 ), Whalen Kathleen (Sold 4 650 shares of value $1 244 420 ), Wyatt Christopher (Sold 0 shares of value $-983 520 ), Wyatt Christopher (Sold 4 900 shares of value $1 241 170 )
Tue, 24 Oct 2023 13:50 GMT Analysts Are Bullish on These Healthcare Stocks: HCA Healthcare (HCA), NRX Pharmaceuticals (NRXP)- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.